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oint-of-Care
latelet Function Analysis
eady for Prime Time?*
lisabeth Mahla, MD, Mark J. Antonino, BS,
daya S. Tantry, PHD,
aul A. Gurbel, MD, FACC
altimore, Maryland
ual antiplatelet therapy is effective in preventing ischemic
omplications after acute coronary syndromes and stenting.
owever, recurrent ischemic events and bleeding remain
mportant concerns. Current practice guidelines advocate a
one-size-fits-all” antiplatelet strategy based on clinical trials
hat have largely avoided measurements of platelet function
n the individual patient (1). Therefore, two burning unan-
wered questions remain: 1) is recurrent ischemic event
ccurrence primarily explained by high on-treatment plate-
et reactivity; and 2) is bleeding primarily explained by low
latelet reactivity? The correct answers to these questions
re crucial for the successful development of new antithrom-
otic strategies designed to improve patient outcomes.
See page 849
The unpredictable response to clopidogrel and the pres-
nce of high on-treatment platelet reactivity to adenosine
iphosphate (ADP) in selected patients has been repeatedly
hown by multiple methods that assess P2Y12 function,
ncluding light transmittance aggregometry (LTA), point-
f-care whole-blood analysis of aggregation to fibrinogen
oated beads, whole-blood flow cytometry to assess intra-
ellular signaling and the expression of activation-
ependent receptors, and thrombelastography (2,3).
Poor responsiveness to clopidogrel was first linked to
schemic risk after stenting in patients with ST-segment
levation myocardial infarction in 2003. In a small study,
atetzky et al. (4) found that patients who showed the
owest quartile of platelet inhibition had a 40% prob-
bility for a recurrent cardiovascular event within 6 months.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Sinai Center for Thrombosis Research, Baltimore, Maryland. Dr. Gurbel
as received research grants and honoraria from Schering-Plough, Haemoscope,t
straZeneca, Medtronic, Lilly/Daiichi Sankyo, Sanofi-Aventis, Boston Scientific,
ayer Healthcare, Portola Pharmaceuticals, and Pozen.n the same year, Barragan et al. (5) reported an associa-
ion between the platelet reactivity index measured by
asodilator-stimulated phosphoprotein (VASP) phosphory-
ation and the occurrence of stent thrombosis. In 2005 we
eported an association between on-treatment ADP-
nduced platelet aggregation measured by LTA, 6-month
ost-stenting ischemic events, and stent thrombosis (6,7).
iven the variability in baseline (i.e., pre-clopidogrel)
DP-induced platelet aggregation, we hypothesized that
n-treatment platelet reactivity may be a better predictor of
ost-stenting ischemic events than responsiveness to clopi-
ogrel (8). Since 2005 numerous investigations have re-
orted a relationship between high on-treatment platelet
eactivity to ADP and in-hospital, 6-month, 1-year, and
-year post-stenting ischemic risk including stent thrombo-
is (6,9–14).
In this issue of the Journal, Sibbing et al. (15) report the
esults of a large 2-center prospective study designed to
nvestigate the relationship between platelet reactivity to
DP and the 30-day cumulative incidence of definite stent
hrombosis as defined by the Academic Research Consor-
ium. The authors measured platelet reactivity with a new
mpedance aggregometer also known as the Multiplate
nalyzer (Dynabyte, Munich, Germany). This device mea-
ures aggregation in whole blood, thus enhancing the ease of
easurement by obviating centrifugation as required by
TA. The same authors have previously reported that
ultiplate measurements correlate with LTA, the most
idely utilized technique in translational research studies
hat have associated platelet reactivity with post-stenting
schemic risk (16). The highest quintile was used as the
re-specified cut point for high platelet reactivity, termed
lopidogrel low responders by the authors and used to size
he study. However, the latter term is somewhat misleading
ecause assessment of clopidogrel responsiveness requires a
re-treatment measurement of platelet function, a measure-
ent that was absent in the current study. Platelet function
as determined only once in the catheterization laboratory
nd associated with the occurrence of 30-day stent throm-
osis. There were 7 definite stent thromboses in the
lopidogrel low responders and 3 in the clopidogrel re-
ponders. The association of a single measurement with the
ccurrence of a post-stent thrombotic event is the most
ommonly reported link in the literature. Currently, there is
n enormous void in our knowledge regarding the stability
f the high platelet reactivity phenotype. Serial measure-
ents of platelet function are lacking in the literature and in
he current article. In a similar fashion to other studies
6,10), Sibbing et al. (15) performed a receiver-operator
haracteristic (ROC) curve analysis to determine the opti-
al platelet function cut point associated with stent throm-
osis. They identified a cut point of 468 AU as the best
iscriminatory threshold, yielding an area under the curve of
.78 for the prediction of stent thrombosis. The aforemen-
ioned finding was similar to a recent study using LTA, in
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.78 for 2-year post-stent ischemic events (10).
It should be noted that the Sibbing et al. (15) study
nvolved a very heterogeneous group of patients who re-
eived various parenteral antithrombotic regimens for dif-
erent clinical presentations. Although clinical presentation
f coronary artery disease was evaluated as a potential
onfounder in the Cox regression model, parenteral anti-
latelet therapy was not, and therefore a potential indepen-
ent predictive value of the latter is unknown. Moreover,
atients were loaded with clopidogrel irrespective of main-
enance therapy. The timing of platelet function measure-
ents was also similarly highly variable, but was performed
t least 2 h after clopidogrel loading. Prior investigations
ave clearly shown that an assessment of clopidogrel re-
ponse is dependent on dose and the time at which platelet
unction is measured after treatment. It is therefore not
urprising that clopidogrel low-responsive patients had a
horter interval of time between loading and platelet func-
ion analyses. Determining whether patients treated with
lopidogrel for sufficient time to allow a pharmacodynamic
ffect and who have high platelet reactivity measured by a
oint-of-care device are truly at risk for a thrombotic event
s of major importance in this field of investigation.
It is curious that despite not allowing maximum platelet
nhibition by clopidogrel to occur in all patients before
latelet function analyses, the investigators still found a
elationship between their measurement and the primary
nd point. It is unknown whether the relationship would
emain the same if platelet function measurements were
onducted at a uniform pre-specified time allowing the full
ntiplatelet effect of clopidogrel.
Have the investigators successfully answered the two
urning questions with their investigation? They must be
ongratulated for showing an association between a cutoff
alue of high platelet reactivity measured by a point-of-care
evice and the occurrence of stent thrombosis in a large
tudy. Their study further strengthens the hypothesis that
schemic events largely occur above a threshold of platelet
eactivity to ADP as measured by an ex vivo method.
owever, given the above limitations, whether ischemic
vent occurrence is primarily explained by high on-
reatment platelet reactivity to ADP remains incompletely
nswered. We believe that caution is warranted in extrapo-
ating the results of this study to different patient popula-
ions and in guiding individualized antiplatelet therapy.
urthermore, this study lacks adequate power to assess the
ssociation between platelet reactivity and bleeding. Thus,
he second question of whether bleeding is primarily ex-
lained by low platelet reactivity remains unanswered. The
ork of Sibbing et al. (15) is definitely a major step forward
o unraveling the mystery of why selected post-stent patients
leed whereas others suffer the dreaded coronary artery
hrombotic event. Continued translational research holds
he promise of marked improvements in clinical outcomes
uided by objective measurements of platelet physiology inhe individual patient. The ultimate goal would be the
otential identification of a therapeutic window for P2Y12
eceptor blockade as shown in Figure 1. The current
vailable data suggest that post-stenting ischemic events are
ssociated with a P2Y12 reactivity cut point. However, there
s a very large gap in our understanding of the relationship
f P2Y12 reactivity to bleeding.
eprint requests and correspondence: Dr. Paul A. Gurbel,
inai Center for Thrombosis Research, Shapiro Building, Suite
09, 2401 West Belvedere Avenue, Baltimore, Maryland 21215.
-mail: pgurbel@lifebridgehealth.org.
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Figure 1 The Potential Relationship of P2Y12
Reactivity to Bleeding and Ischemic Events
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